Menu
Menu
― Marquis Pierre Simon de Laplace
― Marquis Pierre Simon de Laplace
Let’s rephrase this as: “If we could know the relative abundance of all the proteins and all metabolites in a person’s blood at a given time, we could make fairly accurate predictions about their future health trajectories.”
Gregory Penner and Ximena Vedoya had the vision to change the healthcare system by introducing a top-down mathematical approach and displace the existing hypothesis-based paradigm. The hypothesis-based approach has reached the limit of its effectiveness, leading to the creation of silos based on attempts to prevent a cause of death. A top-down approach would implicitly be more holistic and personalized.
They seized on aptamers as a key tool to deliver this vision. They founded and grew NeoVentures Biotechnology Inc. in Canada to being the world leader in fee-for-service aptamer development. Stil, they thought that the aptamer platform itself was under-utilized in this one aptamer – one target mindset. The library itself was more powerful, as it could translate the information from biological fluids to DNA code.
They founded a second company in Paris, initially named NeoNeuro, now NeoVentures Biotechnology Europe. The objective of this company is to realize the capacity of aptamer libraries to characterize everything all at once, and this required an almost complete reinvention of aptamer science. They have finally realized their vision with the creation of the Aptamarker Platform.
The Aptamarker platform has the potential to catalyze a paradigm shift in healthcare, moving from a reactive approach focused on treating diseases, to a proactive strategy centered around prevention and maintaining optimal health. This hypothesis-free, deep data, AI based platform will revolutionize our understanding of health on a personal level.
Let’s rephrase this as: “If we could know the relative abundance of all the proteins and all metabolites in a person’s blood at a given time, we could make fairly accurate predictions about their future health trajectories.”
Gregory Penner and Ximena Vedoya had the vision to change the healthcare system by introducing a top-down mathematical approach and displace the existing hypothesis-based paradigm. The hypothesis-based approach has reached the limit of its effectiveness, leading to the creation of silos based on attempts to prevent a cause of death. A top-down approach would implicitly be more holistic and personalized.
They seized on aptamers as a key tool to deliver this vision. They founded and grew NeoVentures Biotechnology Inc. in Canada to being the world leader in fee-for-service aptamer development. Stil, they thought that the aptamer platform itself was under-utilized in this one aptamer – one target mindset. The library itself was more powerful, as it could translate the information from biological fluids to DNA code.
They founded a second company in Paris, initially named NeoNeuro, now NeoVentures Biotechnology Europe. The objective of this company is to realize the capacity of aptamer libraries to characterize everything all at once, and this required an almost complete reinvention of aptamer science. They have finally realized their vision with the creation of the Aptamarker Platform.
The Aptamarker platform has the potential to catalyze a paradigm shift in healthcare, moving from a reactive approach focused on treating diseases, to a proactive strategy centered around prevention and maintaining optimal health. This hypothesis-free, deep data, AI based platform will revolutionize our understanding of health on a personal level.
Let’s rephrase this as: “If we could know the relative abundance of all the proteins and all metabolites in a person’s blood at a given time, we could make fairly accurate predictions about their future health trajectories.”
Gregory Penner and Ximena Vedoya had the vision to change the healthcare system by introducing a top-down mathematical approach and displace the existing hypothesis-based paradigm. The hypothesis-based approach has reached the limit of its effectiveness, leading to the creation of silos based on attempts to prevent a cause of death. A top-down approach would implicitly be more holistic and personalized.
They seized on aptamers as a key tool to deliver this vision. They founded and grew NeoVentures Biotechnology Inc. in Canada to being the world leader in fee-for-service aptamer development. Stil, they thought that the aptamer platform itself was under-utilized in this one aptamer – one target mindset. The library itself was more powerful, as it could translate the information from biological fluids to DNA code.
They founded a second company in Paris, initially named NeoNeuro, now NeoVentures Biotechnology Europe. The objective of this company is to realize the capacity of aptamer libraries to characterize everything all at once, and this required an almost complete reinvention of aptamer science. They have finally realized their vision with the creation of the Aptamarker Platform.
The Aptamarker platform has the potential to catalyze a paradigm shift in healthcare, moving from a reactive approach focused on treating diseases, to a proactive strategy centered around prevention and maintaining optimal health. This hypothesis-free, deep data, AI based platform will revolutionize our understanding of health on a personal level.